Table 1 Baseline clinical characteristics of the study population
Characteristics | Study dataset (n = 83) | |||
|---|---|---|---|---|
ALL patients | pCR (n = 22) | No-pCR (n = 61) | P | |
Age (years, SD) | 63.83 (13.64) | 61.76 (9.21) | 64.54 (13.64) | 0.21 |
Sex (N, %) | ||||
Male | 60 (72.3) | 15 (81.8) | 45 (73.8) | 0.208 |
Female | 23 (27.7) | 7 (18.2) | 16 (26.2) | |
CEA (N, %) | ||||
Abnormal | 48 (57.8) | 15 (68.2) | 33 (54.1) | 0.251 |
Normal | 35 (42.2) | 7 (31.8) | 28 (45.9) | |
CA199 (N, %) | ||||
Abnormal | 22 (26.5) | 9 (36.4) | 13 (21.3) | 0.235 |
Normal | 59 (73.5) | 13 (59.1) | 46 (75.4) | |
DIS (cm, SD) | 5.02 (2.28) | 6.03 (1.92) | 4.62 (2.28) | 0.012* |
CRM status (N, %) | ||||
Positive | 50 (60.2) | 12 (54.5) | 38 (62.3) | 0.524 |
Negative | 33 (39.8) | 10 (45.5) | 23 (37.7) | |
mrEMVI status (N, %) | ||||
Positive | 36 (22.2) | 8 (36.4) | 28 (45.9) | 0.474 |
Negative | 47 (77.8) | 14 (63.6) | 33 (54.1) | |
Tumor stage (N, %) | ||||
T1 − 2 | 9 (10.8) | 2 (90.9) | 7 (11.5) | 0.736 |
T3 − 4 | 74 (89.2) | 20 (90.9) | 54 (88.5) | |
Lymph node (N, %) | ||||
N0 | 11 (13.3) | 3 (13.6) | 8 (13.1) | 0.289 |
N1 − 2 | 72 (86.7) | 19 (86.4) | 53 (86.9) | |